Interim results from an open-label extension study of briakinumab for the treatment of moderate to severe psoriasis

被引：0
|
作者：
Langley, Richard G. [1 ]
Williams, David [2 ]
Papp, Kim [3 ]
Olds, Michele [2 ]
机构：
[1] Dalhousie Univ, Halifax, NS, Canada
[2] Abbott Labs, Abbott Pk, IL 60064 USA
[3] Prob Med Res, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2012年 / 66卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB195 / AB195
页数：1
相关论文
共 50 条
  • [21] Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
    Feagan, Brian G.
    Panes, Julian
    Ferrante, Marc
    Kaser, Arthur
    D'Haens, Geert R.
    Sandborn, William J.
    Louis, Edouard
    Neurath, Markus F.
    Franchimont, Denis
    Dewit, Olivier
    Seidler, Ursula
    Kim, Kyung-Jo
    Selinger, Christian
    Padula, Steven J.
    Herichova, Ivona
    Robinson, Anne M.
    Wallace, Kori
    Zhao, Jun
    Minocha, Mukul
    Othman, Ahmed A.
    Soaita, Adina
    Visvanathan, Sudha
    Hall, David B.
    Boecher, Wulf O.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10): : 671 - 680
  • [22] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Puig, Luis
    Lebwohl, Mark
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Gomez, Natalie Nunez
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 486 - 495
  • [23] Interim Results from Continuation-the Ongoing, Open-Label, Extension Study of Ecallantide for the Treatment of Acute Attacks of Hereditary Angioedema
    MacGinnitie, A. J.
    Pullman, W. E.
    Horn, P. T.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB165 - AB165
  • [24] Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
    Thaci, Diamant
    Puig, Luis
    Merola, Joseph F.
    Jullien, Denis
    Costanzo, Antonio
    Wang, Maggie
    Deherder, Delphine
    Lopez Pinto, Jose M.
    Lebwohl, Mark
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4733 - 4735
  • [25] Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study
    Wallace, D. J.
    Hobbs, K.
    Clowse, M. E. B.
    Petri, M.
    Strand, V.
    Pike, M.
    Merrill, J. T.
    Leszczynski, P.
    Neuwelt, C. M.
    Jeka, S.
    Houssiau, F.
    Keiserman, M.
    Ordi-Ros, J.
    Bongardt, S.
    Kilgallen, B.
    Galateanu, C.
    Kalunian, K.
    Furie, R.
    Gordon, C.
    ARTHRITIS CARE & RESEARCH, 2016, 68 (04) : 534 - 543
  • [26] Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
    Strober, Bruce
    Tada, Yayoi
    Mrowietz, Ulrich
    Lebwohl, Mark
    Foley, Peter
    Langley, Richard G.
    Warren, Richard B.
    Wang, Maggie
    Vanvoorden, Veerle
    Szilagyi, Balint
    Ciaravino, Valerie
    Paul, Carle
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 749 - 759
  • [27] Efficacy and safety of adalimumab in a 120-week open-label extension study in patients with moderate to severe chronic plaque psoriasis
    Papp, Kim
    Leonardi, Craig
    Gordon, Kenneth
    Frevert, Lisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB193 - AB193
  • [28] Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Up to 5 Years of Follow-up
    Papp, Kim A.
    Lebwohl, Mark G.
    Puig, Lluis
    Ohtsuki, Mamitaro
    Beissert, Stefan
    Liu, Jie
    Wu, Tianshuang
    Sinvhal, Ranjeeta
    Soliman, Ahmed M.
    Chen, Michael M.
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB62 - AB62
  • [29] Five-year open-label extension study of safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis
    Paller, Amy S.
    Siegfried, Elaine C.
    Pariser, David M.
    Rice, Kara Creamer
    Trivedi, Mona
    Iles, Jan
    Collier, David H.
    Kricorian, Greg
    Langley, Richard G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB251 - AB251
  • [30] Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study
    Percy, Alan K.
    Neul, Jeffrey L.
    Benke, Timothy A.
    Berry-Kravis, Elizabeth M.
    Glaze, Daniel G.
    Marsh, Eric D.
    An, Di
    Bishop, Kathie M.
    Youakim, James M.
    MED, 2024, 5 (09):
12345